**Black Diamond Therapeutics, Inc. Reports Financial Results and Operational Progress in Annual Filing**

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, released its financial results and provided an operational update in its recent 10-K filing. The company, focused on developing MasterKey therapies targeting oncogenic mutations, reported a net income of $22.4 million for the year ended December 31, 2025, a significant shift from the $69.7 million net loss reported for the previous fiscal year. This turnaround was primarily attributed to a $70 million upfront payment received from Servier Pharmaceuticals LLC related to a global licensing agreement for BDTX-4933.

The company's research and development expenses decreased from $51.3 million in 2024 to $33.6 million in 2025, reflecting operational efficiencies and the out-licensing of BDTX-4933. General and administrative expenses also saw a reduction, decreasing from $27.5 million to $16.6 million due to corporate restructuring efforts. As of March 11, 2026, Black Diamond Therapeutics employed 21 full-time individuals, with 12 dedicated to research and development and 9 to administrative functions.

Operationally, Black Diamond Therapeutics is advancing its lead program, silevertinib, through a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) patients. Initial data from the trial showed a 60% Objective Response Rate (ORR) in frontline NSCLC patients with non-classical EGFR mutations. The company is also preparing to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed patients with EGFR-altered glioblastoma (GBM) in the second quarter of 2026. In the first quarter of 2025, Black Diamond Therapeutics out-licensed BDTX-4933 to Servier Pharmaceuticals LLC, granting Servier global rights to develop and commercialize the asset.

Looking ahead, Black Diamond Therapeutics believes its existing cash, cash equivalents, and investments of $128.7 million as of December 31, 2025, will be sufficient to fund operations into the second half of 2028. The company plans to present updated results from the Phase 2 NSCLC trial in the second quarter of 2026 and is exploring potential partnerships for the pivotal development of silevertinib. The company's strategy includes generating Phase 2 clinical trial results for silevertinib in EGFRm NSCLC to enable a potential pivotal trial and conducting a Phase 2 clinical trial for silevertinib in newly diagnosed patients with EGFR altered GBM to support a potential pivotal study.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies—oral, small molecule inhibitors targeting families of oncogenic mutations across genetically defined cancers. Its proprietary MAP drug discovery engine identifies and inhibits mutation-driven cancer proteins with selectivity and brain penetration. Key programs focus on EGFR-mutant non-small cell lung cancer and glioblastoma. The company aims to address resistance and expand targeted treatment options for patients with limited therapies.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.